Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 77

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 77
---
, and a substantial portion of our operating expenses are payable, in currencies other than the U.S. dollar.

Exchange rate fluctuations
may have an adverse impact on our future revenues, if any, or expenses as presented in the financial statements. We may in the future
use financial instruments, such as forward foreign currency contracts, in its management of foreign currency exposure. These contracts
would primarily require us to purchase and sell certain foreign currencies with or for U.S. dollars at contracted rates. We may be exposed
to a credit loss in the event of non-performance by the counterparties of these contracts. In addition, these financial instruments may
not adequately manage our foreign currency exposure. Our results of operations could be adversely affected if we are unable to successfully
manage currency fluctuations in the future.

Effects of Inflation

Inflation generally
affects Revium by increasing its research and development expenses. Revium does not believe that inflation and changing prices had a
significant impact on its results of operations for any periods presented herein, but may have a significant, adverse impact in 2025.

<div align='center'>46

DESCRIPTION OF BUSINESS

Overview</div>

We are a pre-clinical stage biopharmaceutical
company focused on the development and eventual commercialization of innovative and proprietary nanoparticle-based therapies. We focus
on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing effectiveness
while reducing side effects. We are developing unique lipid-based platforms for a variety of potential uses, including areas with high
unmet-needs such as antimicrobial resistance and solid tumors.

Our work is inspired by Prof. Barenholz,
one of the world’s leaders in this field and one of the original innovators behind liposomal drug delivery. His decades of
research have shaped some of today’s most important cancer treatments like Doxil ®. At Revium Rx, we’re taking this
legacy further, using our technology to develop next-generation therapies to help meet some of the most urgent medical
needs.

Our programs are focused on infectious diseases,
including antibiotic-resistant infections, solid tumors and a novel approach to vaccination. We leverage advanced lipid-based delivery
systems with the aim of enhancing the safety, efficacy, and clinical utility of established therapeutics, while also exploring potential
new uses for existing compounds. Our proprietary technology builds on principles demonstrated by liposomal drug delivery products such
as Doxil®, the first FDA-approved nanomedicine. By encapsulating potent therapeutics in our lipid